Financial Performance - In Q3 2023, the company achieved a revenue of RMB 598.19 million, representing a year-on-year growth of 8.41%[17] - The net profit attributable to shareholders reached RMB 122.23 million, an increase of 19.70% compared to the same period last year[17] - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 118.77 million, up 22.29% year-on-year[17] - For the first three quarters of 2023, the company reported a total revenue of RMB 1.75 billion, a 15.42% increase from RMB 1.51 billion in the same period last year[19] - The net profit attributable to shareholders for the first three quarters was RMB 386.53 million, reflecting a significant growth of 70.31% year-on-year[19] - The diluted earnings per share for the quarter were RMB 0.6504, a 70.74% increase compared to the same period last year[8] - Operating profit for the first three quarters of 2023 was approximately $457.82 million, compared to $276.32 million in the previous year, indicating an increase of about 65.6%[33] - Net profit for the first three quarters of 2023 was approximately $395.08 million, a significant rise from $233.80 million in the same period of 2022, reflecting an increase of about 69%[33] - The total comprehensive income for the first three quarters of 2023 was approximately $396.00 million, compared to $234.08 million in the previous year, marking an increase of about 69.1%[34] Research and Development - Research and development expenses totaled RMB 33.93 million in Q3 2023, accounting for 5.67% of operating revenue, a decrease of 1.20 percentage points from the previous year[8] - Research and development expenses decreased to approximately $102.60 million in 2023 from $121.70 million in 2022, a reduction of about 15.7%[32] - The company launched several new products, including the NapoleonTM Endoscopic Polyp Measurement Device and Ensure Single-use Coagulation Forceps in Argentina, received certification in July 2023[36] - New product certifications in the U.S. included various biopsy forceps and stents, with certifications received in July and August 2023[38] - The company is actively expanding its product registration in both domestic and international markets[28] - The company is expanding its market presence with new product launches in multiple countries, including Germany and Brazil, throughout 2023[38] Assets and Liabilities - The company's total assets at the end of the reporting period were RMB 4.19 billion, up 7.59% from RMB 3.89 billion at the end of the previous year[8] - As of September 30, 2023, total assets increased to CNY 4,189,719,391.61 from CNY 3,894,020,049.96 as of December 31, 2022, representing a growth of approximately 7.6%[40] - Current assets rose to CNY 3,147,058,408.54, up from CNY 2,982,741,149.20, indicating an increase of about 5.5%[40] - Non-current assets totaled CNY 1,042,660,983.07, up from CNY 911,278,900.76, which is an increase of around 14.4%[43] - The total liabilities slightly increased to CNY 620,290,729.54 from CNY 619,553,923.59, showing a marginal growth of about 0.1%[44] - The company's equity attributable to shareholders rose to CNY 3,511,418,308.77 from CNY 3,225,001,207.85, representing an increase of approximately 8.9%[44] Cash Flow - The company’s cash flow from operating activities increased by 136.10% year-on-year, amounting to RMB 359.18 million[9] - The company reported cash inflows from operating activities of CNY 1,791,077,407.19 for the first three quarters of 2023, compared to CNY 1,729,016,599.67 in the same period of 2022, marking an increase of approximately 3.6%[48] - The net cash flow from operating activities increased to ¥359,177,957.50, compared to ¥152,130,691.78 in the previous period, reflecting a significant improvement[49] - Cash inflow from investment activities totaled ¥997,115,514.58, down from ¥1,545,309,428.47, indicating a decrease in investment returns[49] - The net cash flow from investment activities was -¥1,529,252,872.06, a decline from a positive ¥48,533,900.03 in the previous period, highlighting increased investment expenditures[49] - The total cash and cash equivalents at the end of the period decreased to ¥660,725,878.76 from ¥1,184,196,317.48, reflecting a significant drop in liquidity[49] Shareholder Information - The total number of common shareholders at the end of Q3 2023 is 10,850[21] - The largest shareholder, Shenzhen Zhongke Investment Co., Ltd., holds 42,251,300 shares, representing 22.49% of the total shares[21] - The second-largest shareholder, Nanjing Xinweichuang Enterprise Management Consulting Co., Ltd., holds 36,073,614 shares, representing 19.20% of the total shares[21] - Huakang Limited, the third-largest shareholder, holds 13,112,579 shares, representing 6.98% of the total shares[23] - The company has not disclosed any financing or margin trading activities among its top shareholders, except for Nanjing Xinweichuang, which has engaged in securities lending[22] - The company reported that the total number of shares held by the top 10 unrestricted shareholders is 42,251,300[21] - The company has not reported any significant changes in shareholder relationships or actions among the top shareholders[22] Dividend and Interest Payments - The company paid ¥103,386,880.78 in dividends and interest, slightly up from ¥100,870,018.58, indicating a stable dividend policy[49]

证券代码：688029 证券简称：南微医学 公告编号：2023-037 南微医学科技股份有限公司部分高级管理人员 集中竞价减持股份结果公告 2023 年 7 月 8 日，公司在上海证券交易所网站（www.sse.com.cn）披露了 《南微医学科技股份有限公司部分高级管理人员集中竞价减持股份计划公告》 （公告编号：2023-029）。公司高级副总裁张锋先生拟通过集中竞价方式减持公 司股份不超过 8,820 股，不超过公司总股本的 0.0047%。截至 10 月 27 日，本次 减持计划期限届满，张锋先生未实施减持。 上述减持主体无一致行动人。 1 股东名称 股东身份 持股数量 （股） 持股比例 当前持股股份来源 张锋 董事、监事、 高级管理人员 35,280 0.0188% 其他方式取得：35,280 股 一、集中竞价减持主体减持前基本情况 二、集中竞价减持计划的实施结果 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 高级管理人员持股的基本情况 本次减持计划实施前，南微医学科技股份有限公司(以 ...

本次减持计划实施前，Huakang Limited 持有南微医学科技股份有限公司（以 下简称"公司"）13,889,822 股，占公司总股本 7.3942%。上述股份来源为公司 首次公开发行股票并上市前取得股份，及该等股份于公司 2022 年实施资本公积 转增股本时获得股份，上述股份已于 2022 年 7 月 22 日起上市流通。 南微医学科技股份有限公司 持股 5%以上股东减持股份结果 暨减持达到 1%的公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 大股东持股的基本情况 证券代码：688029 证券简称：南微医学 公告编号：2023-036 减持计划的实施结果情况 2023 年 6 月 17 日，公司在上海证券交易所网站（www.sse.com.cn）披露了 《南微医学科技股份有限公司持股 5%以上股东减持股份计划公告》（公告编号： 2023-028）。公司股东 Huakang Limited 拟通过集中竞价、大宗交易方式减持公 司股份合计不超过 5,635,422 股。 近日，公司收 ...

（http://roadshow.sseinfo.com/） 证券代码：688029 证券简称：南微医学 公告编号：2023-035 南微医学科技股份有限公司 关于参加 2023 年半年度医疗器械专场集体业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 投资者可于 2023 年 9 月 1 日（星期五）17:00 前将有关问题通过电子 邮件的形式发送至公司投资者关系邮箱 nwyx@micro-tech.com.cn。公司将 在说明会上对投资者普遍关注的问题进行回答。 南微医学科技股份有限公司（以下简称"公司"）已于 2023 年 8 月 8 日在上 海证券交易所网站（www.sse.com.cn）披露《2023 年半年度报告》。为便于广大 投资者更全面深入地了解公司 2023 年上半年经营成果、财务状况，公司计划于 2023 年 9 月 5 日参加上海证券交易所主办的 2023 年半年度医疗器械专场集体业 绩说明会，就投资者关心的问题进行线上交流。 一、 说明会类型 本次投资者说明会以视频加 ...

重要内容提示： 大股东持股的基本情况 本次减持计划实施前，Huakang Limited 持有南微医学科技股份有限公司（以 下简称"公司"）13,889,822 股，占披露本次减持计划时公司总股本的 7.3942%。 上述股份来源为公司首次公开发行股票并上市前取得的股份，及该等股份于公司 2022 年实施资本公积转增股本时获得股份，上述股份已于 2022 年 7 月 22 日起 上市流通。 减持计划的进展情况 2023 年 6 月 17 日，公司在上海证券交易所网站（www.sse.com.cn）披露了 《南微医学科技股份有限公司持股 5%以上股东减持股份计划公告》（公告编号： 2023-028）。公司股东 Huakang Limited 拟通过集中竞价、大宗交易方式减持公 司股份合计不超过 5,635,422 股。 证券代码：688029 证券简称：南微医学 公告编号：2023-034 南微医学科技股份有限公司 持股 5%以上股东减持股份进展公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 公司于 202 ...

证券代码：688029 证券简称：南微医学 公告编号：2023-033 南微医学科技股份有限公司 持股 5%以上股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 大股东持股的基本情况 截至本公告日，深圳市中科招商创业投资有限公司（以下简称"中科招商"） 持有南微医学科技股份有限公司（以下简称"公司"）股份 42,251,300 股，占公司 总股本的 22.4924%。上述股份来源为公司首次公开发行股票并上市前取得的股 份，及该等股份于公司 2022 年实施资本公积转增股本时获得股份，上述股份已 于 2022 年 7 月 22 日起上市流通。 减持计划的主要内容 公司股东中科招商因自身资金需求，拟通过上海证券交易所交易系统以集中 竞价、大宗交易方式减持公司股份合计不超过 7,513,896 股，其中拟通过证券交 易所集中竞价交易方式进行减持的，将于减持计划公告披露之日起 15 个交易日 之后的180日内减持公司股份不超过3,756,948股；拟通过大宗交易方式减持的， 将于本减 ...

Financial Performance - In 2022, the company achieved total operating revenue of 1,980.14 million RMB, an increase of 1.72% compared to the previous year[28]. - The net profit attributable to the parent company was 331.57 million RMB, a decrease of 15.58% year-on-year, after excluding share-based payment and income tax effects[28]. - The net cash flow from operating activities increased by 44.68%, primarily due to an increase in cash received from sales of goods[28]. - The company's total revenue for Q3 was 551,809,768.89 RMB, showing an increase from Q2's 517,601,645.53 RMB, representing a growth of approximately 6.5%[30]. - Net profit attributable to shareholders for Q3 reached 102,108,506.77 RMB, up from 81,477,004.78 RMB in Q2, marking a growth of about 25.5%[30]. - The net cash flow from operating activities in Q3 was 114,143,865.14 RMB, a significant improvement compared to -23,322,108.23 RMB in Q1[30]. - The company's revenue for 2022 was approximately RMB 1.98 billion, representing a year-over-year increase of 1.72% compared to RMB 1.95 billion in 2021[51]. - The net profit attributable to shareholders for 2022 was approximately RMB 330.59 million, an increase of 1.80% from RMB 324.75 million in 2021[51]. - The net cash flow from operating activities increased by 44.68% to approximately RMB 250.14 million in 2022, compared to RMB 172.89 million in 2021[51]. - The company's total assets as of the end of 2022 were approximately RMB 3.89 billion, a 7.22% increase from RMB 3.63 billion at the end of 2021[51]. - The company's net assets attributable to shareholders increased by 9.57% to approximately RMB 3.23 billion at the end of 2022, compared to RMB 2.94 billion at the end of 2021[51]. - The basic earnings per share for 2022 were RMB 1.7655, reflecting a 1.48% increase from RMB 1.7396 in 2021[51]. Market and Product Development - The company is focused on expanding its market presence and enhancing its product offerings in the minimally invasive medical technology sector[19]. - The company anticipates strong market demand for medical services in 2023, driven by high-quality development initiatives and a recovering economy[42]. - The company aims to leverage opportunities from domestic policy shifts towards "cost reduction in medical insurance" and "domestic substitution" to enhance its market position[42]. - The company plans to focus on technological advancements and innovation to overcome existing technical barriers and improve product offerings[42]. - The global endoscopic device market was valued at $6 billion in 2022, with an expected growth rate of 6% from 2021 to 2024[66]. - The disposable endoscope market grew from $10.84 million in 2016 to $52.83 million in 2020, with a compound annual growth rate (CAGR) of 48.6%, projected to reach $3.3928 billion by 2025[66]. - The disposable endoscope market in China is projected to grow from 11.2 million RMB in 2016 to 1.42 billion RMB by 2025, with a CAGR of 107.6%[66]. - The company is actively exploring structural investment opportunities in major innovation projects to support future growth[59]. - The company is expanding its product line and accelerating the development of disposable endoscopes, targeting new growth opportunities in critical care medicine[91]. Research and Development - The R&D expenditure as a percentage of revenue increased to 8.35% in 2022, up from 7.85% in 2021[51]. - The total R&D investment reached 60,312.81 million, with a significant increase in the number of projects under development[110]. - The company has a well-structured R&D team with 76 master's degree holders and 239 bachelor's degree holders, contributing to a strong foundation for continuous innovation[113]. - The company has received two National Science and Technology Progress Second Prizes, highlighting its strong innovation capabilities in the endoscopic field[81]. - The company has developed nearly 30 core technologies in endoscopic diagnosis and treatment, including six major categories such as dilation and biopsy, achieving multiple world-first and China-first technological results[86]. - The company has received regulatory approvals for new products in various regions, including the EU and the United States, enhancing its market presence[129]. - The company is focusing on the development of innovative medical devices, including microwave ablation generators and digital controllers, to strengthen its competitive edge[123][129]. Corporate Governance and Sustainability - The company emphasizes sustainable development and has improved its environmental management system, successfully passing the ISO 14001 environmental management system audit[5]. - The company is committed to corporate governance and adheres to relevant laws and regulations, continuously optimizing its internal system[5]. - The company has implemented lean management practices to enhance decision-making, assessment mechanisms, and talent development[59]. - The company has been recognized as a national high-tech enterprise, indicating its commitment to innovation and technology advancement[94]. - The company has established collaborations with several universities and hospitals for its R&D projects, enhancing its innovation capabilities[94]. Challenges and Risks - The company faces risks from intensified market competition and potential price reductions in the medical device sector[145]. - The company is implementing strategies to mitigate risks related to overseas sales and currency fluctuations[145]. - The company emphasizes maintaining product quality as a core competitive advantage, with ongoing improvements in quality control measures[145].

Financial Performance - The company's revenue for Q1 2023 reached RMB 550.10 million, representing a year-on-year increase of 24.26%[17] - Net profit attributable to shareholders was RMB 101.49 million, reflecting a significant growth of 133.98% compared to the same period last year[17] - The basic earnings per share increased by 133.25% to RMB 0.5403, driven by the rise in net profit attributable to shareholders[7] - Net profit for the first quarter reached approximately 103.40 million, compared to 45.52 million in the same period last year, representing a year-over-year increase of 127.5%[36] - The company's operating profit rose to approximately 121.35 million, significantly higher than 50.87 million from the previous year, marking an increase of 138.5%[36] Research and Development - Research and development expenses totaled RMB 35.40 million, accounting for 6.44% of operating revenue, a decrease of 2.73 percentage points year-on-year[5] - The company has allocated resources towards research and development of new technologies to maintain competitive advantage in the market[33] - Research and development expenses decreased to RMB 35,400,007.86 in Q1 2023 from RMB 40,606,208.52 in Q1 2022, reflecting a reduction of 12.4%[52] Assets and Liabilities - The total assets at the end of the reporting period were RMB 3.97 billion, an increase of 1.85% from the end of the previous year[5] - The total liabilities decreased to approximately 585.33 million from 619.55 million, a reduction of about 5.5%[32] - The total equity attributable to shareholders increased to approximately 3.33 billion, up from 3.23 billion, reflecting a growth of about 3.4%[32] - Cash and cash equivalents at the end of Q1 2023 totaled RMB 1,197,861,714.10, compared to RMB 845,290,400.25 at the end of Q1 2022[58] Market Expansion and Product Development - The company registered new products in both domestic and international markets, including a Single-use Video Pancreaticobiliary Scope in the US and various biopsy forceps in Japan[11] - The company has received multiple product registrations in Thailand, Ecuador, Germany, South Korea, and the USA, indicating ongoing product development and market expansion[25] - The company updated several product standards in China, including the tracheal stent and disposable endoscope injection needle, reflecting compliance with new regulations[27] - The company is actively pursuing regulatory approvals for new medical devices, which is crucial for market entry and competitiveness[27] - The company is exploring international markets, as evidenced by product registrations in multiple countries[25] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 11,000[22] - Major shareholders include Shenzhen Zhongke Investment Co., holding 22.49% and Nanjing Xinweichuang Management Consulting Co., holding 19.18%[23] - The shareholder structure shows no significant pledges or restrictions on shares, indicating a stable ownership base[23] Cash Flow and Expenses - Cash flow from operating activities for the period was RMB 65.95 million, with no applicable year-on-year comparison[17] - The company reported a decrease in accounts payable from approximately 332.31 million to 269.66 million, a decline of about 19%[32] - Sales expenses increased to RMB 111,180,111.27 in Q1 2023, up from RMB 88,706,290.84 in Q1 2022, marking a rise of 25.4%[52] - Tax expenses rose to RMB 5,118,784.29 in Q1 2023 from RMB 3,562,243.81 in Q1 2022, an increase of 43.7%[52] - The company recorded a net increase in cash and cash equivalents of RMB -677,499,186.72 in Q1 2023, compared to RMB -122,170,443.68 in Q1 2022[58] Strategic Focus - The first quarter report for 2023 indicates a focus on enhancing product offerings and adapting to market needs[30] - The first quarter report highlights strategic initiatives aimed at improving operational efficiency and market reach[30] - The company is focusing on expanding its market presence and enhancing product development strategies to drive future growth[33]

证券代码：688029 证券简称：南微医学 公告编号：2023-013 南微医学科技股份有限公司 关于参加 2022 年度医疗器械专场集体业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： （http://roadshow.sseinfo.com/） 投资者可于 2023 年 4 月 27 日（星期四）17:00 前将有关问题通过电子 邮件的形式发送至公司投资者关系邮箱 nwyx@micro-tech.com.cn。公司将 在说明会上对投资者普遍关注的问题进行回答。 南微医学科技股份有限公司（以下简称"公司"）将于 2023 年 4 月 26 日在 上海证券交易所网站（www.sse.com.cn）披露《2022 年年度报告》。为便于广大 投资者更全面深入地了解公司 2022 年度经营成果、财务状况，公司计划于 2023 年 4 月 28 日参加上海证券交易所主办的 2022 年度医疗器械专场集体业绩说明 会，就投资者关心的问题进行线上交流。 一、 说明会类型 本次投资者说明会以视频加线上文字 ...

Financial Performance - The company achieved operating revenue of RMB 551.81 million in Q3 2022, representing a year-on-year increase of 7.31%[2] - Net profit attributable to shareholders was RMB 102.11 million, a decrease of 2.98% compared to the same period last year[2] - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 97.12 million, an increase of 33.96% year-on-year[2] - The cumulative operating revenue for the first three quarters of 2022 reached RMB 1.51 billion, an increase of 8.87% year-on-year[3] - The company reported a net profit of RMB 226.96 million for the first three quarters, a decrease of 8.68% year-on-year[3] - Total operating revenue for the first three quarters of 2022 reached ¥1,512,101,641.63, an increase of 8.9% compared to ¥1,388,953,773.62 in the same period of 2021[16] - Net profit for the third quarter of 2022 was ¥233,796,364.70, a decrease of 8.9% from ¥256,631,858.18 in the same quarter of 2021[19] - Basic earnings per share for the period were RMB 0.5453, down 3.27% from the same period last year[3] - Earnings per share for the third quarter of 2022 were ¥1.2121, down from ¥1.3313 in the same period last year[20] Assets and Liabilities - The total assets at the end of the reporting period were RMB 3.80 billion, an increase of 4.69% compared to the end of the previous year[3] - As of September 30, 2022, the company's total assets reached approximately CNY 3.80 billion, an increase from CNY 3.63 billion at the end of 2021, representing a growth of about 4.6%[13] - The company's total liabilities decreased slightly to CNY 580.33 million from CNY 601.64 million, reflecting a decrease of about 3.5%[14] - The company's total liabilities amounted to ¥635,571,416.04, slightly down from ¥641,444,869.77 in the previous year[18] - The total equity attributable to shareholders reached ¥3,111,701,714.24, an increase from ¥2,943,321,990.43 year-over-year[18] Cash Flow - The cash inflow from operating activities for the first three quarters of 2022 was CNY 1,729,016,599.67, an increase of 21.4% compared to CNY 1,425,075,648.60 in the same period of 2021[21] - The net cash flow from operating activities for the first three quarters of 2022 was CNY 152,130,691.78, a decrease of 13.9% from CNY 176,770,982.80 in the previous year[22] - The total cash inflow from investment activities was CNY 1,545,309,428.47, down 30.8% from CNY 2,234,762,524.59 in the same period of 2021[22] - The net cash flow from investment activities for the first three quarters of 2022 was CNY 48,533,900.03, a significant decrease of 87.4% compared to CNY 384,922,267.04 in 2021[22] - The cash inflow from financing activities was CNY 100,000,000.00, compared to CNY 548,500.00 in the same period of 2021[22] - The net cash flow from financing activities was -CNY 7,608,813.74, an improvement from -CNY 32,311,944.06 in the previous year[22] - The cash and cash equivalents at the end of the period were CNY 1,184,196,317.48, compared to CNY 1,165,289,354.08 at the end of the same period in 2021[23] Research and Development - Research and development expenses totaled RMB 37.90 million, accounting for 6.87% of operating revenue, a decrease of 1.30 percentage points year-on-year[3] - Research and development expenses for the third quarter of 2022 were ¥121,698,108.19, compared to ¥101,025,381.15 in the same quarter of 2021, indicating a growth of 20.5%[18] Inventory and Receivables - Inventory levels increased significantly to CNY 513.17 million, compared to CNY 394.29 million in the previous year, reflecting a rise of about 30.2%[13] - The company's accounts receivable decreased to CNY 330.00 million from CNY 354.95 million, showing a decline of approximately 7.0%[13] Strategic Developments - The company received multiple product registrations in international markets, including Brazil and the United States, for various medical devices, enhancing its product portfolio[12] - The company has introduced new products, including the ProTrap Luma specimen tray and digital controllers, which received registration certificates in Brazil and Germany, respectively[12] - The company plans to expand its market presence through new product launches and potential acquisitions in the upcoming quarters[11] - The company’s gross profit margin is expected to improve due to the introduction of higher-margin products and operational efficiencies[11] Financial Improvements - The company reported a significant reduction in short-term borrowings, which stood at CNY 100 million, indicating a strategic move to lower debt levels[14] - The company received CNY 11,091,453.17 in tax refunds, a significant increase from CNY 336,045.93 in the previous year[21] - The total cash outflow from operating activities was CNY 1,576,885,907.89, an increase of 26.3% compared to CNY 1,248,304,665.80 in 2021[22] - The cash outflow for employee compensation was CNY 475,081,771.99, up 31.3% from CNY 361,757,235.74 in the previous year[22]